Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3372979 | 0.86 | ESR1 (0.39) | CYP3A4CYP2C9GAAESR1ESR2 | |
| SCHEMBL3402960 | 0.86 | ESR1 (0.39) | CYP3A4CYP2C9GAAESR1ESR2 | |
| SCHEMBL5017407 | 0.85 | NR3C1 (0.43) | CYP3A4GAAESR1ESR2MIF | |
| SCHEMBL3371001 | 0.85 | NR3C1 (0.43) | CYP3A4GAAESR1ESR2MIF | |
| SCHEMBL3372793 | 0.84 | APP (0.42) | ESR1ESR2MIFCA12CA1 | |
| SCHEMBL5095387 | 0.84 | APP (0.42) | ESR1ESR2MIFCA12CA1 | |
| SCHEMBL3374300 | 0.84 | CHRNA7 (0.38) | GAAESR1ESR2MIFCA12 | |
| SCHEMBL5391741 | 0.82 | CYP3A4 (0.44) | CYP3A4CYP2C9GAAESR1ESR2 | |
| SCHEMBL5085176 | 0.81 | EPHX2 (0.39) | ESR1ESR2MIFCA12CA1 | |
| SCHEMBL5017451 | 0.81 | EPHX2 (0.39) | ESR1ESR2MIFCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537091-B1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS | HOFFMANN LA ROCHE (CH) | 2010-10-06 | — | — | EP | disclosed |
| EP-1551814-B1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-07-23 | — | — | EP | disclosed |
| US-7348349-B2 | Oxazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1572203-B1 | SUBSTITUTED 4-ALKOXYOXAZOL DERIVATIVES AS PPAR AGONISTS | HOFFMANN LA ROCHE (CH) | 2007-11-07 | — | — | EP | disclosed |
| US-7109225-B2 | Antidiabetic agents; hypotensive agents; anticholesterol agents; antilipemic agents; antiinflammatory agents; antiproliferative agents | HOFMANN-LA ROCHE INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050267180-A1 | Novel oxazole derivatives | BINGGELI ALFRED | 2005-12-01 | — | — | US | disclosed |
| US-6969725-B2 | Oxazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-11-29 | — | — | US | disclosed |
| EP-1572203-A1 | SUBSTITUTED 4-ALKOXYOXAZOL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| EP-1551814-A1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-13 | — | — | EP | disclosed |
| EP-1537091-A1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| US-6809110-B2 | NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID | HOFFMANN-LA ROCHE INC. | 2004-10-26 | — | — | US | disclosed |
| US-20040157898-A1 | Novel substituted oxazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-12 | — | — | US | disclosed |
| US-20040116487-A1 | Novel oxazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040110807-A1 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-10 | — | — | US | disclosed |
| WO-2004041275-A1 | SUBSTITUTED 4-ALKOXYOXAZOL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004031162-A1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004020420-A1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267180-A1 | Novel oxazole derivatives | NR1H3, NR1H2, PPARD | CYP3A4 221/4885CYP2C9 358/4885GAA 4007/4885 |
| US-20040157898-A1 | Novel substituted oxazole derivatives | OXA1L, SLC5A1, GPR119 | CYP3A4 72/4885CYP2C9 70/4885GAA 589/4885 |
| US-20040110807-A1 | Thiazole derivatives | SLC5A1, GPR119, INSR | CYP3A4 468/4885CYP2C9 589/4885GAA 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.